Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bicalutamide adjuvant to radical prostatectomy.

William A See

    Reviews in Urology
    |September 21, 2006
    PubMed
    Summary

    Adjuvant hormonal therapy with bicalutamide (Casodex) significantly improves progression-free survival after prostatectomy for localized prostate cancer. This treatment offers clear benefits, especially for high-risk patients, reducing recurrence risk.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Editorial Commentary.

    Urology practice·2023
    Same author

    The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy.

    The Prostate·2021
    Same author

    Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial.

    Practical radiation oncology·2021
    Same author

    Accurate segmentation of prostate cancer histomorphometric features using a weakly supervised convolutional neural network.

    Journal of medical imaging (Bellingham, Wash.)·2020
    Same author

    Factors Influencing Patient Selection of Urologists.

    Urology·2019
    Same author

    Pathogen-Boosted Adoptive Cell Transfer Therapy Induces Endogenous Antitumor Immunity through Antigen Spreading.

    Cancer immunology research·2019

    Area of Science:

    • Oncology
    • Urology
    • Pharmacology

    Background:

    • Prostate cancer recurrence after radical prostatectomy impacts up to 50% of men within 10 years.
    • Limited data exist on adjuvant hormonal therapy's efficacy in the post-prostatectomy setting.
    • Novel treatments are needed to mitigate the risk of prostate cancer recurrence.

    Purpose of the Study:

    • To evaluate the efficacy of immediate adjuvant bicalutamide (Casodex) therapy post-radical prostatectomy.
    • To assess the impact of bicalutamide on progression-free survival and prostate-specific antigen (PSA) progression.
    • To identify patient subgroups benefiting most from adjuvant bicalutamide treatment.

    Main Methods:

    • Analysis of data from the bicalutamide (Casodex) Early Prostate Cancer program.
    • Comparison of immediate adjuvant bicalutamide 150 mg/day versus standard management after radical prostatectomy.
    • Evaluation of progression-free survival and PSA progression as primary endpoints.

    Main Results:

    • Bicalutamide 150 mg/day demonstrated clear benefits in progression-free survival.
    • Significant improvements were observed in prostate-specific antigen progression.
    • The highest risk patient subgroups showed the greatest enhancement in progression-free survival.

    Conclusions:

    • Immediate adjuvant bicalutamide therapy is effective in improving outcomes after radical prostatectomy for localized prostate cancer.
    • Bicalutamide offers a valuable treatment option for reducing recurrence and progression.
    • Risk stratification is important for optimizing adjuvant therapy selection in prostate cancer patients.

    Related Experiment Videos